Pfizer (NY:PFE)

27.80 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Apple's Price Warning Sends Memory Chips To A Record, Accenture Cracks 18% ↗

June 19, 2026

Via Chartmill

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook ↗

June 18, 2026

Pfizer’s recent drug approvals give the company something to build on, with shareholders looking for evidence that cost cuts and newer medicines can keep the 2026 earnings outlook on track.

Via The Motley Fool

Topics Intellectual Property Stocks

Thursday's session: most active stock in the S&P500 index ↗

June 18, 2026

Via Chartmill

These S&P500 stocks have an unusual volume in today's session ↗

June 18, 2026

Via Chartmill

Pfizer Stock Drops Today As CFO Steps Down In August ↗

June 18, 2026

Pfizer shares are slipping Thursday after it announced that Chief Financial Officer Dave Denton will leave the organization.

Via Benzinga

Pfizer Announces Chief Financial Officer Transition

June 18, 2026

From Pfizer Inc.

Via Business Wire

Consumer Watchdog Honors Michael A. Kelly with 2026 Lifetime Legal Achievement Award

June 17, 2026

June 17, 2026 -- The award recognizes distinguished attorneys and public-interest advocates whose careers have advanced consumer protection, challenged corporate misconduct, and improved public...

Via 24-7 Press Release

3 S&P 500 Stocks Worth Your Attention

June 17, 2026

The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innova...

Via StockStory

Topics Stocks

How to Build a Retirement Income Plan That Lasts Through a High-Inflation Decade ↗

June 16, 2026

If you haven't planned for inflation, and possibly high inflation, your nest egg's purchasing power could shrink alarmingly.

Via The Motley Fool

Topics Bonds ETFs Economy

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

June 16, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Via StockStory

A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack

June 15, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav...

Via StockStory

Topics Artificial Intelligence

Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit Growth ↗

June 15, 2026

Pfizer's business may be in better shape than investors think.

Via The Motley Fool

Topics Earnings Intellectual Property

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗

June 13, 2026

Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe.

Via The Motley Fool

Topics Bonds Intellectual Property

Have S&P 500 Index Funds, Often Touted as the Best Stock Investments, Become Dangerous? There's a Worrisome Development -- and a Possibly Better Alternative. ↗

June 14, 2026

The hard-earned dollars you park in a standard S&P 500 index fund may not be distributed the way you think they are.

Via The Motley Fool

Topics ETFs Stocks

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About ↗

June 12, 2026

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Via The Motley Fool

Thursday's session: most active stock in the S&P500 index ↗

June 11, 2026

Via Chartmill

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗

June 11, 2026

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

Via MarketBeat

Topics Intellectual Property

Why Pfizer Stock Popped Today ↗

June 11, 2026

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Via The Motley Fool

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? ↗

June 11, 2026

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.

Via The Motley Fool

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase ↗

June 09, 2026

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics...

Via MarketBeat

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗

June 09, 2026

Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate...

Via MarketBeat

2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 We Brush Off

June 09, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study ↗

June 08, 2026

Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.

Via Benzinga

Curious about the most active S&P500 stocks in today's session? ↗

June 08, 2026

Via Chartmill

Hemostat Powder Market Size, Analysis Report By 2035 ↗

June 08, 2026

The most recent research report on the "Hemostat Powder Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, an

Via Talk Markets

Topics Economy

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

June 08, 2026

From Pfizer Inc.

Via Business Wire

Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗

June 08, 2026

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

Via The Motley Fool

Topics Intellectual Property Stocks

3 Dividend Stocks to Buy Hand Over Fist in June ↗

June 07, 2026

They sport recent dividend yields of 3.25%, 6.7%, and a whopping 7.7%.

Via The Motley Fool

Topics Intellectual Property

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. ↗

June 06, 2026

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Via The Motley Fool

Topics Intellectual Property

Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems ↗

June 06, 2026

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.